Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 6/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 2/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | LDHB | P07195 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20100914 | 0.91 | CSF1R (0.71) | CSF1RBRAFLDHALDHB | |
| SCHEMBL20100905 | 0.88 | CSF1R (0.68) | CSF1RBRAFLDHALDHB | |
| SCHEMBL18023935 | 0.85 | CSF1R (0.59) | CSF1RNTRK1LMNASMN1; SMN2MEN1 | |
| Seralutinib SCHEMBL17324860 | 0.81 | CSF1R (0.72) | CSF1RBRAFLDHALDHB | |
| SCHEMBL20100911 | 0.81 | CSF1R (0.74) | CSF1RBRAFLDHALDHB | |
| SCHEMBL20101067 | 0.81 | CSF1R (0.72) | CSF1RBRAFLDHALDHB | |
| Seralutinib SCHEMBL30738060 | 0.81 | CSF1R (0.72) | CSF1RBRAFLDHALDHB | |
| SCHEMBL18023934 | 0.81 | CSF1R (0.88) | CSF1RLMNASMN1; SMN2BRAFLDHA | |
| Seralutinib SCHEMBL20100984 | 0.81 | CSF1R (0.72) | CSF1RBRAFLDHALDHB | |
| Seralutinib SCHEMBL18867902 | 0.81 | CSF1R (0.72) | CSF1RBRAFLDHALDHB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3054937-B1 | SPRAY DRY FORMULATIONS | PULMOKINE INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20160235742-A1 | SPRAY DRY FORMULATIONS | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235742-A1 | SPRAY DRY FORMULATIONS | FLT1, KDR, ERBB2 | CSF1R 169/4885NTRK1 45/4885LMNA 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.